Eris Lifesciences announced the launch of a low-cost generic semaglutide product in India under the brand name Sundae, with its smallest available dosage priced at 1,290 rupees per month, roughly $13.8. The initial offering is a vial containing 2 mg of the active ingredient intended for diabetes treatment.
The company has partnered with Natco Pharma for the semaglutide introduction; Natco set the price for its lowest 2 mg dose at the same 1,290 rupee monthly level. Eris signaled plans to expand the delivery format in April by bringing a pen device to market that will be available in three dosages. Pricing disclosed for the pen shows the lowest 2 mg option at 4,000 rupees per month and the highest 8 mg pen at 4,500 rupees per month.
This move places Eris among dozens of Indian drug manufacturers rolling out generic semaglutide products as the patent held by Danish drugmaker Novo Nordisk lapses on March 20. Among larger rivals, Dr Reddy's is expected to introduce its own version on Saturday, illustrating the rapid entry of multiple competitors into the market.
Price comparisons in the market underscore the cost differential between the newly launched generic and established branded treatments. On a monthly basis, Sundae's smallest dose is 88% less expensive than Novo Nordisk's Wegovy and 91% cheaper than the lowest-dose offering from U.S. drugmaker Eli Lilly's Mounjaro.
The initial Sundae launch centers on vial dosing, with the pen device intended to provide additional dosing options when it becomes available in April. The announced pricing shows a substantial gap between vial and pen formats for the same 2 mg active ingredient amount, according to the company's public pricing structure.
With multiple Indian manufacturers preparing to enter the market following the patent expiry, the semaglutide landscape in India is poised for notable price competition. The rollout by Eris and its partner Natco highlights how quickly generics can be introduced following patent milestones, and the announced pen device launch will expand patient access options if it proceeds as scheduled in April.